Molnupiravir 200 mg

Molnupiravir 200 mg is the first oral antiviral of its kind to be authorized for COVID-19. Its unique “error catastrophe” mechanism ensures that even if the virus attempts to replicate, the resulting copies are defective and cannot continue the infection.

Key Clinical Benefits

• Reduced Hospitalization: Clinically shown to significantly lower the risk of hospital admission when started within 5 days of symptom onset.

• Oral Convenience: Unlike Remdesivir, which requires clinical infusion, Molnupiravir is taken at home as a simple pill.

• Variant Resistance: Because it targets the fundamental replication process of the RNA, it remains effective against multiple evolving strains of the virus.

• Rapid Viral Clearance: Helps patients test negative faster by stopping the production of infectious viral particles.

Administration & Safety Protocols

1. Early Intervention: Treatment must begin as soon as possible after a positive COVID-19 diagnosis and within 5 days of symptom onset.

2. Standard Dosage: The typical adult dose is 800 mg (four 200 mg tablets) taken every 12 hours for 5 consecutive days.

3. Completion of Course: It is vital to finish the full 5-day course, even if you start to feel better, to ensure the virus is fully suppressed.

4. Food & Drink: May be taken with or without food. Swallow the tablets whole; do not break or crush them.

5. Pregnancy Warning: Not recommended during pregnancy. Effective contraception must be used during treatment and for a specified period afterward (4 days for females, 3 months for males).